

ASX Announcement

Medibio Limited – 19 July 2019



Medibio Signs Second Compass Group PLC Pilot for ilumen™

Highlights:

- Compass employees in its Offshore and Remote division in the United Kingdom will take part in the ilumen™ well-being pilot commencing in late September.
 - ilumen™ will provide participants with access to a mobile and web application for early screening of mental health symptoms.
 - The Compass Group PLC (Compass Group), is the world's leading food service provider which employs or engages 600,000 people and generates annual revenues of £23.2Billion.
-

Melbourne, Australia and Minneapolis, MN – 19 July 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a health technology company announces that it has signed a second commercial agreement with Compass Group PLC for its corporate health product, ilumen™.

Compass Group PLC, is a British multinational and the world's leading food service company with annual revenues of £23.2 billion. It operates in around 45 countries and employs and engages c.600,000 people worldwide. Compass provides support services across the core sectors of Defense, Offshore & Remote; Business & Industry; Healthcare & Seniors; Education and Sports & Leisure.

As part of the Health & Well-being element of its global 'Purpose' strategy, Compass Group implements various programs to support and improve the mental well-being and physical health of its workforce and its clients' workforce. ilumen™ fits into this strategy by providing participants with early screening for symptoms of depression, anxiety, and stress. The ilumen™ biometric data and subjective assessments provides users with a 'well-being snapshot' that they use to monitor and make improvements over time; whilst also providing Compass management with de-identified aggregate data to better support and manage the mental well-being of their workforce.

"We are pleased to announce our continuing relationship with Compass Group PLC, in particular the signing of a second pilot in their Offshore and Remote Division. It is well known that mental health is an important focus in offshore and remote locations. Through early screening of mental health symptoms, we are delighted to assist Compass in their effort to improve the mental well-being of their workforce in these locations," said Jennifer Solitario, Sr. VP, Corporate Health.

ASX Announcement

Medibio Limited – 19 July 2019



– ENDS –

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:	Website: www.medibio.com.au
Medibio Media Enquiries: Kristi Hamilton Director, Strategic Communications Medibio Limited kristi.hamilton@medibio.com.au T: +1 952 232 0934	Australian Investor Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231
Corporate Health Enquiries: Renee Stanton-Horne Operations and Account Manager renee.stanton.horne@medibio.com.au	